AT
The company develops a gene editing technology platform that utilizes RNA biomarkers for targeted cell depletion in cancer therapies. This approach enables early treatment for patients by precisely identifying and eliminating cancerous cells.
Updated 4 months ago
Funding
Funding not disclosed
Funding rounds are not available yet.
Founders
Product
Features
- The company develops a gene editing technology platform that utilizes RNA biomarkers for targeted cell depletion in cancer therapies. This approach enables early treatment for patients by precisely identifying and eliminating cancerous cells.